Fluticasone

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.

Fluticasone Propionate Respules (0.5mg per 2ml) is an inhaled corticosteroid nebulizer suspension on the WHO Model List framework. Delivers high topical anti-inflammatory potency to bronchial mucosal tissues. Indicated for maintenance management of severe persistent asthma and acute exacerbations in pediatric and adult patients unable to coordinate inhaler devices.

Azelastine Hydrochloride (140mcg) and Fluticasone Propionate (50mcg) Nasal Spray is a fixed-dose second-generation H1-antihistamine and corticosteroid combination on the WHO Model List framework. Azelastine provides rapid-onset (within 15 minutes) blockade of histamine H1 receptors, relieving sneezing, nasal itching, and rhinorrhea. Fluticasone provides sustained 24-hour suppression of mucosal inflammation, relieving stubborn nasal congestion. Proven significantly superior to either monotherapy for Moderate-to-Severe Allergic Rhinitis and seasonal rhinoconjunctivitis.

Fluticasone Propionate / Fluticasone Furoate Nasal Spray (27.5mcg, 50mcg per spray) is a synthetic trifluorinated corticosteroid on the WHO Model List of Essential Medicines. It binds with exceptionally high affinity to glucocorticoid receptors in the nasal mucosa, inhibiting mediator release (histamine, leukotrienes, cytokines) with virtually negligible systemic oral bioavailability (<0.1%). Indicated for management of seasonal allergic rhinitis, perennial allergic rhinitis, and nasal polyposis.

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.

Formoterol Fumarate (6mcg) and Fluticasone Propionate (250mcg Inhaler / Powder for Inhalation) combines a rapid-onset, long-acting beta-2 agonist with a high-affinity synthetic fluorinated corticosteroid. Delivers fast bronchodilation within minutes along with comprehensive mucosal anti-inflammatory suppression. Indicated for regular maintenance treatment of persistent asthma in patients not adequately controlled on inhaled corticosteroids alone.

Fluticasone Propionate / Fluticasone Furoate Nasal Spray (27.5mcg, 50mcg per spray) is a synthetic trifluorinated corticosteroid on the WHO Model List of Essential Medicines. It binds with exceptionally high affinity to glucocorticoid receptors in the nasal mucosa, inhibiting mediator release (histamine, leukotrienes, cytokines) with virtually negligible systemic oral bioavailability (<0.1%). Indicated for management of seasonal allergic rhinitis, perennial allergic rhinitis, and nasal polyposis.

Formoterol Fumarate (6mcg) and Fluticasone Propionate (250mcg Inhaler / Powder for Inhalation) combines a rapid-onset, long-acting beta-2 agonist with a high-affinity synthetic fluorinated corticosteroid. Delivers fast bronchodilation within minutes along with comprehensive mucosal anti-inflammatory suppression. Indicated for regular maintenance treatment of persistent asthma in patients not adequately controlled on inhaled corticosteroids alone.

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.